Role of Direct Antiviral Agents in Treatment of Chronic Hepatitis C Infection in Renal Transplant Recipients

Table 6

Comparison of study pattern, demographics, virological profile, and response to therapy with other published studies.

	Kamar et al. [24]	Sawinski et al. [25]	Lin et al. [26]	Fernández et al. [27]	Present study
Study period	2014-2015	2014-2015	2013–2015	2015-2016	2015–2017
Study design	Prospective	Prospective	Retrospective	Retrospective	Prospective
Study center	Single-center	Single-center	Multicenter	Multicenter, national	Single-center
Place of study	France	USA	USA	Spain	India
Sample size	25	20	24	103	45
Age in years			60 (34–70)	55 (27–74)	38 (23–68)
M : F	15 : 10	16 : 4	19 : 5	69 : 34	23 : 22
Time since renal transplantation	146 months (1–329)	888 days (341–1621)	96 months (2–492)	147 months (1–561)	36 months (1–120)
Genotype:
1	19	17	21	85	15
3	1	0	0	7	30
2, 4, 6	5	3	3	10	0
HCV RNA level	Mean  log IU/ml	Median 6.5 log IU/ml (range 6.3–7 log IU/ml)	Median 1,922,552 IU/ml (1060–22,600,000 IU/ml)	Median 6.61 log IU/ml (2.87–7.79 log IU/ml)	Median 5,42,648 IU/ml (range 1189–55,028,534 IU/ml)
Virological response:
RVR	88% (22/25)	-	-	59%	97.78%
ETR	100%	95%	83.33%	100%	97.78%
SVR 12	100%	100%	91%	98%	100%
Immunosuppression:
Tacrolimus based	19 (76%)	19 (95%)	19 (79.16%)	75 (72.82%)	39 (86.67%)
Cyclosporine based	5 (20%)	1 (5%)	3 (12.5%)	12 (11.65%)	4 (8.89%)
mTOR inhibitor based	1 (4%)	0	1 (4.16%)	7 (6.8%)	2 (4.44%)